CMPS gives back the majority of its 4.2% gain within 15 trading days absent a data or partnership catalyst; no M&A among CMPS/ATAI/MMED/NUMI in 8 weeks.

When a stock jumps without a concrete reason — like a major trial result or a partnership deal — it usually drifts back down. COMPASS Pathways' recent 4.2% gain fits that pattern. Meanwhile, none of the major publicly traded psychedelic companies (COMPASS, ATAI Life Sciences, Mind Medicine, or Numinus) appear to be in merger or acquisition talks. Without a real catalyst — new data, a buyout, or a licensing deal — the pop is expected to erase itself by August 25, 2026.

Catalyst-free pops mean-revert. The sector trades on Phase 3 readouts and licensing deals — none pending among these names near-term.